Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia.

Background: The use of granulocyte colony-stimulating factor (G-CSF) as a prophylaxis against febrile neutropenia (FN) is well documented in the literature; however, the therapeutic use of G-CSF in the treatment of FN remains controversial. This study assessed the efficacy of adjunctive G-CSF in the treatment of FN by evaluating clinical outcomes.

Methods: This was a single-center, prospective cohort study conducted at the National Cancer Center in Singapore.